Carotis Intima-Media Thickness, Lipid Accumulation Product Index, Cardiovascular Risk Calculation Score and Their Relationship with Monocyte to HDL Ratio in Middle-Aged Women with Polycystic Ovary Syndrome

ABSTRACT Objectives: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women in the reproductive age and also associated with many comorbidities that increase the risk of cardiovascular disease in later ages. This study explores the potential correlation between the monocyte to HDL ratio (MHR) and established cardiovascular risk factors in women with PCOS. Material and method: This cross-sectional analysis includes PCOS-diagnosed women (n=40) in menopausal transition over 40 years old, and a control group of non-PCOS healthy women (n=40) matched for age and body-mass index (BMI). Various parameters, including demographic and anthropometric measurements, lipid profiles, carotis intima-media thickness (CIMT), free androgen index (FAI), lipid accumulation product (LAP) index, homeostasis model assessment-insulin resistance (HOMA-IR), MHR, and SCORE2 risk scores were compared between the groups.Results: Results indicate no significant differences in age, BMI, smoking, lipid profiles, fasting glucose, insulin levels, MHR, LAP index, HOMA-IR, and SCORE2 scores. However, sex-hormone binding globulin and total testosterone were higher in the PCOS group (p<0.001). Metabolic syndrome rates, FAI, and average CIMT were notably higher in the PCOS group (p=0.045, p=0.003, p=0.022). MHR was positively correlated with LAP index, HOMA-IR, FAI, and left CIMT (r=0.235; r=0.297; r=0.28; r=0.215; respectively).Conclusion: In conclusion, PCOS women exhibit higher metabolic syndrome rates and average CIMT measurements compared to healthy age and BMI matched counterparts. Positive correlations of the MHR with various risk factors emphasize the importance of assessing cardiovascular risk in this population and shows that MHR can be used as a much cheaper predictor of cardiovascular risk compared to other predictors in perimenopausal PCOS patients.